PRICING SHEET TEMPLATE - Attachment 1.xlsx
XLSX spreadsheet 22 KB Posted
- Solicitation number
- 15DDHQ25Q00000010
About this file
This is a Pricing Sheet Template for a Drug Enforcement Administration (DEA) contract opportunity focused on evaluating the abuse potential of various substances through in vivo pharmacological studies. The document outlines pricing details for five distinct ordering periods, with each period structured identically and covering multiple types of scientific assays: Locomotor Activity Assay, Drug Discrimination Assay, and Cannabinoid Tetrad Assay. Each ordering period involves testing 17 total drugs (15 test drugs and 2 reference drugs), with specific line items for assay costs, incidental costs, and drug costs.
The first ordering period is specifically for evaluating synthetic opioids, while the subsequent four ordering periods are dedicated to studying hallucinogenic substances. Although the pricing template shows zero dollar amounts, it provides a standardized framework for potential contractors to complete with their specific pricing. The contract opportunity (Solicitation Number 15DDHQ25Q00000010) is issued by the Department of Justice's Drug Enforcement Administration and seeks investigational study results and methodology descriptions for abuse potential assessments of synthetic cannabinoids and phytocannabinoids using in vivo pharmacological studies.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| 15DDHQ25Q00000010 Amendment 0001 03192025.pdf | ||
| Pricing Sheet Templalte.xlsx | XLSX spreadsheet | |
| RFQ 15DDHQ25Q00000010.pdf | ||
| Sample BPA Call Order - Attachment 2.xlsx | XLSX spreadsheet |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Summary
| PERIOD | Total Cost Per Ordering Period |
| ORDERING PERIOD 1 | $ - 0 |
| ORDERING PERIOD 2 | $ - 0 |
| ORDERING PERIOD 3 | $ - 0 |
| ORDERING PERIOD 4 | $ - 0 |
| ORDERING PERIOD 5 | $ - 0 |
| Total Cost | $ - 0 |
ORDERING PERIOD 1
| PRICING SHEET TEMPLATE: ATTACHMENT 1 | |
| Title: | Evaluation of Abuse Potential of Synthetic Opioids and Other Depressants Using In Vivo Pharmacological Studies |
| Agency: | Drug Enforcement Administration | |||||
| ORDERING PERIOD 1 | ||||||
| CLIN Line Item | Assay | Quantity | Unit | Unit Price | Estimated Total Price | |
| 1 | Locomotor Activity Assay Cost | 10 | EA | $ - 0 | ||
| Locomotor Activity Assay Incidental Cost | 10 | EA | $ - 0 | |||
| 2 | Drug Discrimination (monthly maintenance of training drug) Assay Cost | 3 | EA | $ - 0 | ||
| Drug Discrimination (training drug) Incidental Cost | 3 | EA | $ - 0 | |||
| Drug Discrimination of test drug Assay Cost | 10 | EA | $ - 0 | |||
| 3 | Drug Discrimination of test drug Incidental Cost | 10 | EA | $ - 0 | ||
| Cannabinoid Tetrad Assay | 10 | EA | $ - 0 | |||
| 4 | Cannabinoid Tetrad Assay incidental cost | 10 | EA | $ - 0 | ||
| 5 | Drug Cost Not to Exceed | 10 | EA | $ - 0 | ||
| TOTAL COST ($) | $ - 0 | |||||
| ** NOTE: 15 Test Drugs + 2 Reference Drugs = 17 TOTAL DRUGS | ||||||
| 1 TOTAL |
ORDERING PERIOD 2
| PRICING SHEET TEMPLATE: ATTACHMENT 1 | |
| Title: | Evaluation of Abuse Potential of Hallucinogenic Substances Using In Vivo Pharmacological Studies |
| Agency: | Drug Enforcement Administration | ||||
| ORDERING PERIOD 2 | |||||
| CLIN Line Item | Assay | Quantity | Unit | Unit Price | Estimated Total Price |
| 1001 | Locomotor Activity Assay Cost | 10 | EA | $ - 0 | |
| Locomotor Activity Assay Incidental Cost | 10 | EA | $ - 0 | ||
| 1002 | Drug Discrimination (monthly maintenance of training drug) Assay Cost | 3 | EA | $ - 0 | |
| Drug Discrimination (training drug) Incidental Cost | 3 | EA | $ - 0 | ||
| Drug Discrimination of test drug Assay Cost | 10 | EA | $ - 0 | ||
| 1003 | Drug Discrimination of test drug Incidental Cost | 10 | EA | $ - 0 | |
| Cannabinoid Tetrad Assay | 10 | EA | $ - 0 | ||
| 1004 | Cannabinoid Tetrad Assay incidental cost | 10 | EA | $ - 0 | |
| 1005 | Drug Cost Not to Exceed | 10 | EA | $ - 0 | |
| TOTAL COST ($) | $ - 0 | ||||
| ** NOTE: 15 Test Drugs + 2 Reference Drugs = 17 TOTAL DRUGS |
ORDERING PERIOD 3
| PRICING SHEET TEMPLATE: ATTACHMENT 1 | |
| Title: | Evaluation of Abuse Potential of Hallucinogenic Substances Using In Vivo Pharmacological Studies |
| Agency: | Drug Enforcement Administration | ||||
| ORDERING PERIOD 3 | |||||
| CLIN Line Item | Assay | Quantity | Unit | Unit Price | Estimated Total Price |
| 2001 | Locomotor Activity Assay Cost | 10 | EA | $ - 0 | |
| Locomotor Activity Assay Incidental Cost | 10 | EA | $ - 0 | ||
| 2002 | Drug Discrimination (monthly maintenance of training drug) Assay Cost | 3 | EA | $ - 0 | |
| Drug Discrimination (training drug) Incidental Cost | 3 | EA | $ - 0 | ||
| Drug Discrimination of test drug Assay Cost | 10 | EA | $ - 0 | ||
| 2003 | Drug Discrimination of test drug Incidental Cost | 10 | EA | $ - 0 | |
| Cannabinoid Tetrad Assay | 10 | EA | $ - 0 | ||
| 2004 | Cannabinoid Tetrad Assay incidental cost | 10 | EA | $ - 0 | |
| 2005 | Drug Cost Not to Exceed | 10 | EA | $ - 0 | |
| TOTAL COST ($) | $ - 0 | ||||
| ** NOTE: 15 Test Drugs + 2 Reference Drugs = 17 TOTAL DRUGS |
ORDERING PERIOD 4
| PRICING SHEET TEMPLATE: ATTACHMENT 1 | |
| Title: | Evaluation of Abuse Potential of Hallucinogenic Substances Using In Vivo Pharmacological Studies |
| Agency: | Drug Enforcement Administration | ||||
| ORDERING PERIOD 4 | |||||
| CLIN Line Item | Assay | Quantity | Unit | Unit Price | Estimated Total Price |
| 3001 | Locomotor Activity Assay Cost | 10 | EA | $ - 0 | |
| Locomotor Activity Assay Incidental Cost | 10 | EA | $ - 0 | ||
| 3002 | Drug Discrimination (monthly maintenance of training drug) Assay Cost | 3 | EA | $ - 0 | |
| Drug Discrimination (training drug) Incidental Cost | 3 | EA | $ - 0 | ||
| Drug Discrimination of test drug Assay Cost | 10 | EA | $ - 0 | ||
| 3003 | Drug Discrimination of test drug Incidental Cost | 10 | EA | $ - 0 | |
| Cannabinoid Tetrad Assay | 10 | EA | $ - 0 | ||
| 3004 | Cannabinoid Tetrad Assay incidental cost | 10 | EA | $ - 0 | |
| 3005 | Drug Cost Not to Exceed | 10 | EA | $ - 0 | |
| TOTAL COST ($) | $ - 0 | ||||
| ** NOTE: 15 Test Drugs + 2 Reference Drugs = 17 TOTAL DRUGS |
ORDERING PERIOD 5
| PRICING SHEET TEMPLATE: ATTACHMENT 1 | |
| Title: | Evaluation of Abuse Potential of Hallucinogenic Substances Using In Vivo Pharmacological Studies |
| Agency: | Drug Enforcement Administration | ||||
| ORDERING PERIOD 5 | |||||
| CLIN Line Item | Assay | Quantity | Unit | Unit Price | Estimated Total Price |
| 4001 | Locomotor Activity Assay Cost | 10 | EA | $ - 0 | |
| Locomotor Activity Assay Incidental Cost | 10 | EA | $ - 0 | ||
| 4002 | Drug Discrimination (monthly maintenance of training drug) Assay Cost | 3 | EA | $ - 0 | |
| Drug Discrimination (training drug) Incidental Cost | 3 | EA | $ - 0 | ||
| Drug Discrimination of test drug Assay Cost | 10 | EA | $ - 0 | ||
| 4003 | Drug Discrimination of test drug Incidental Cost | 10 | EA | $ - 0 | |
| Cannabinoid Tetrad Assay | 10 | EA | $ - 0 | ||
| 4004 | Cannabinoid Tetrad Assay incidental cost | 10 | EA | $ - 0 | |
| 4005 | Drug Cost Not to Exceed | 10 | EA | $ - 0 | |
| TOTAL COST ($) | $ - 0 | ||||
| ** NOTE: 15 Test Drugs + 2 Reference Drugs = 17 TOTAL DRUGS |
File details come from the government source that posted it. Updated .